BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36198460)

  • 1. Impact and cost-effectiveness of rotavirus vaccination in Niger: a modelling study evaluating alternative rotavirus vaccines.
    Debellut F; Tang K; Clark A; Pecenka C; Assao B; Guindo O; Grais RF; Isanaka S
    BMJ Open; 2022 Oct; 12(10):e061673. PubMed ID: 36198460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of rotavirus vaccination in the Philippines: A modeling study.
    Villanueva-Uy MET; Lam HY; Aldaba JG; Uy TMZ; Valverde HA; Silva MWT; Mooney J; Clark A; Pecenka C
    Vaccine; 2021 Nov; 39(48):7091-7100. PubMed ID: 34753614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of rotavirus vaccination in Mozambique.
    Lourenço Guimarães E; Chissaque A; Pecenka C; Clark A; Vaz B; Banze A; Canana N; Romão C; do Rosário Oliveira Martins M; de Deus N; Debellut F
    Vaccine; 2022 Aug; 40(36):5338-5346. PubMed ID: 35933279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Bergman H; Henschke N; Hungerford D; Pitan F; Ndwandwe D; Cunliffe N; Soares-Weiser K
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD008521. PubMed ID: 34788488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Introduction of rotavirus vaccination in Palestine: An evaluation of the costs, impact, and cost-effectiveness of ROTARIX and ROTAVAC.
    Debellut F; Jaber S; Bouzya Y; Sabbah J; Barham M; Abu-Awwad F; Hjaija D; Ramlawi A; Pecenka C; Clark A; Mvundura M
    PLoS One; 2020; 15(2):e0228506. PubMed ID: 32023295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the potential economic and health impact of rotavirus vaccination in 63 middle-income countries not eligible for Gavi funding: a modelling study.
    Debellut F; Clark A; Pecenka C; Tate J; Baral R; Sanderson C; Parashar U; Atherly D
    Lancet Glob Health; 2021 Jul; 9(7):e942-e956. PubMed ID: 33891885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of rotavirus vaccination in children of Bhutan.
    Pempa ; Luz ACG; Luangasanatip N; Kingkaew P; Adhikari D; Isaranuwatchai W; Choiphel D; Pecenka C; Debellut F
    Vaccine; 2020 Jul; 38(32):5049-5059. PubMed ID: 32522415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness and budget impact analyses for the prioritisation of the four available rotavirus vaccines in the national immunisation programme in Thailand.
    Luangasanatip N; Mahikul W; Poovorawan K; Cooper BS; Lubell Y; White LJ; Teerawattananon Y; Pan-Ngum W
    Vaccine; 2021 Mar; 39(9):1402-1414. PubMed ID: 33531197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of the Rotavac and Rotasiil rotavirus vaccines administered in an interchangeable dosing schedule among healthy Indian infants: a multicentre, open-label, randomised, controlled, phase 4, non-inferiority trial.
    Kanungo S; Chatterjee P; Bavdekar A; Murhekar M; Babji S; Garg R; Samanta S; Nandy RK; Kawade A; Boopathi K; Kanagasabai K; Kamal VK; Kumar VS; Gupta N; Dutta S
    Lancet Infect Dis; 2022 Aug; 22(8):1191-1199. PubMed ID: 35588754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic analysis for national immunization program planning: A case of rotavirus vaccines in Burundi.
    Niyibitegeka F; Riewpaiboon A; Youngkong S; Thavorncharoensap M
    Vaccine; 2021 Feb; 39(8):1272-1282. PubMed ID: 33487467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccines for preventing rotavirus diarrhoea: vaccines in use.
    Soares-Weiser K; Bergman H; Henschke N; Pitan F; Cunliffe N
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008521. PubMed ID: 30912133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-evaluating the cost and cost-effectiveness of rotavirus vaccination in Bangladesh, Ghana, and Malawi: A comparison of three rotavirus vaccines.
    Pecenka C; Debellut F; Bar-Zeev N; Anwari P; Nonvignon J; Shamsuzzaman M; Clark A
    Vaccine; 2018 Nov; 36(49):7472-7478. PubMed ID: 30420039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rotavirus vaccine product switch in Ghana: An assessment of service delivery costs, switching costs, and cost-effectiveness.
    Owusu R; Mvundura M; Nonvignon J; Armah G; Bawa J; Antwi-Agyei KO; Amponsa-Achiano K; Dadzie F; Bonsu G; Clark A; Pecenka C; Debellut F
    PLOS Glob Public Health; 2023; 3(8):e0001328. PubMed ID: 37556413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introducing rotavirus vaccine in eight sub-Saharan African countries: a cost-benefit analysis.
    Okafor CE; Ekwunife OI
    Lancet Glob Health; 2021 Aug; 9(8):e1088-e1100. PubMed ID: 34297961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Product review of the rotavirus vaccines ROTASIIL, ROTAVAC, and Rotavin-M1.
    Skansberg A; Sauer M; Tan M; Santosham M; Jennings MC
    Hum Vaccin Immunother; 2021 Apr; 17(4):1223-1234. PubMed ID: 33121329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of rotavirus gastroenteritis and need of high rotavirus vaccine coverage with early completion of vaccination schedule for protection against rotavirus diarrhea in India: A narrative review.
    Raju B; Parikh RP; Vetter VV; Kolhapure S
    Indian J Public Health; 2019; 63(3):243-250. PubMed ID: 31552856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic assessment of childhood rotavirus vaccination in Bangladesh.
    Sarker AR
    J Infect Public Health; 2023 May; 16(5):816-822. PubMed ID: 37003027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of a heat-stable rotavirus vaccine among children in Niger: Data from a phase 3, randomized, double-blind, placebo-controlled trial.
    Coldiron ME; Guindo O; Makarimi R; Soumana I; Matar Seck A; Garba S; Macher E; Isanaka S; Grais RF
    Vaccine; 2018 Jun; 36(25):3674-3680. PubMed ID: 29752026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, open-labelled, non-inferiority phase 4 clinical trial to evaluate the immunogenicity and safety of the live, attenuated, oral rotavirus vaccine, ROTAVAC® in comparison with a licensed rotavirus vaccine in healthy infants.
    Ella R; Babji S; Ciarlet M; Blackwelder WC; Vadrevu KM
    Vaccine; 2019 Jul; 37(31):4407-4413. PubMed ID: 31178377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.